Shares of Beyondspring Inc (NASDAQ:BYSI) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus target price of $56.00 for the company and are anticipating that the company will post ($0.76) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Beyondspring an industry rank of 164 out of 265 based on the ratings given to its competitors.
A number of equities analysts recently commented on the company. Maxim Group set a $52.00 target price on Beyondspring and gave the stock a “buy” rating in a report on Thursday, December 14th. Zacks Investment Research cut Beyondspring from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Seaport Global Securities assumed coverage on Beyondspring in a report on Tuesday, December 5th. They issued a “buy” rating and a $56.00 target price on the stock. Finally, HC Wainwright set a $60.00 target price on Beyondspring and gave the stock a “buy” rating in a report on Monday, December 4th.
Beyondspring (NASDAQ:BYSI) last announced its earnings results on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.01. research analysts anticipate that Beyondspring will post -4.41 EPS for the current fiscal year.
An institutional investor recently bought a new position in Beyondspring stock. Tanaka Capital Management Inc. acquired a new stake in shares of Beyondspring Inc (NASDAQ:BYSI) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring makes up 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned approximately 0.10% of Beyondspring at the end of the most recent reporting period. 1.22% of the stock is currently owned by institutional investors.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.